4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.…
4D Molecular Therapeutics May Benefit From Upcoming Wet AMD Gene Therapy Data, RBC Says
4D Molecular Therapeutics (NASDAQ: FDMT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 196 employees.
The shares were at 10.23 USD on 20 November 2026, down 2.6% over 52 weeks. Its 52-week range is 6.960 USD to 16.91 USD: the price is 39.5% below the high and 47.0% above the low.
Its market capitalisation is 576.76M USD.
4D Molecular Therapeutics reports return on equity of -27.7% and an operating margin of -222.7%.
It holds more cash than debt, a net cash position of 268.58M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 11 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 28.09 USD is 174.6% above the current price. The next earnings report is expected on 17 March 2027.